Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Feb 12, 2019

SELL
$3.94 - $9.7 $311,260 - $766,300
-79,000 Closed
0 $0
Q2 2018

Aug 09, 2018

BUY
$9.52 - $12.15 $752,080 - $959,850
79,000 New
79,000 $769,000

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Mutual Of America Capital Management LLC Portfolio

Follow Mutual Of America Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mutual Of America Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mutual Of America Capital Management LLC with notifications on news.